dAurAB5

Overview

dAurAB5 is a dual Aurora-A ( DC 50 = 8.8 nM) and Aurora-B ( DC 50 = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of Aurora-A and Aurora-B , reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1 , PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma. (Pink: TTK ligand 2: HY-168542, Blue: Thalidomide-O-COOH: HY-103597, Black: 6-Aminocaproic acid: HY-B0236). (Pink: Aurora A and Aurora B ligand ( HY-168542 ); Blue: Cereblon ligand ( HY-103597 ); Black: linker ( HY-B0236 )).

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Cyclin G-associated Kinase (GAK) | Products > Signaling Pathways > Mps1 | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Aurora Kinase | Products > Signaling Pathways > AAK1

Product Information

• Catalog No.: HY-171770
• CAS No.: 3115765-45-9
• Molecular Formula: C42H49N11O7
• Molecular Weight: 819.91
• Purity: 99.03%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (6.10 mM); Clear solution
• Availability: In-stock

Source

Original product source